NCT01722526View on ClinicalTrials.gov

Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Human Acid Sphingomyelinase Deficiency
Interventions
DRUG

Recombinant human acid sphingomyelinase

Administered intravenously every 2 weeks for 26 weeks

Trial Locations (2)

Unknown

Mount Sinai School of Medicine, New York

St. Mary's Hospital, Manchester

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT01722526 - Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients | Biotech Hunter | Biotech Hunter